Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study

Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study

The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. While randomized clinical trials were in var...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jonathon W. Senefeld, Patrick W. Johnson, Katie L. Kunze, Evan M. Bloch, Noud van Helmond, Michael A. Golafshar, Stephen A. Klassen, Allan M. Klompas, Matthew A. Sexton, Juan C. Diaz Soto, Brenda J. Grossman, Aaron A.R. Tobian, Ruchika Goel, Chad C. Wiggins, Katelyn A. Bruno, Camille M. van Buskirk, James R. Stubbs, Jeffrey L. Winters, Arturo Casadevall, Nigel Paneth, Beth H. Shaz, M. Petersen, Bruce S. Sachais, Matthew Buras, Mikolaj A. Wieczorek, Benjamin Russoniello, Larry J. Dumont, Sarah E. Baker, Ralph Vassallo, John R.A. Shepherd, Pampee P. Young, Nicole Verdun, Peter Marks, Nancy Haley, Robert F. Rea, Louis M. Katz, Vitaly Herasevich, Dan A. Waxman, Emily R. Whelan, Aviv Bergman, Andrew J. Clayburn, M. Kate Grabowski, Kathryn F. Larson, Juan G. Ripoll, Kylie J. Andersen, Matthew N.P. Vogt, Joshua J. Dennis, Riley J. Regimbal, Philippe R. Bauer, Janis E. Blair, Zachary A. Buchholtz, Michaela C. Pletsch, Katherine Wright, Joel T. Greenshields, Michael J. Joyner, R. Scott Wright, Rickey E. Carter, DeLisa Fairweather
Médium: Artigo
Jazyk:angličtina
Vydáno: 2021
On-line přístup:https://doi.org/10.1371/journal.pmed.1003872
https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003872&type=printable
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. While randomized clinical trials were in various stages of development and enrollment, there was an urgent need for widespread access to potential therapeutic agents. The objective of this study is to report on the demographic, geographical, and chronological characteristics of patients in the EAP, and key safety metrics following transfusion of COVID-19 convalescent plasma.

Podobné jednotky